Hydreight Tech Stock Price, News & Analysis

Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) has been named to the 2025 TSX Venture 50™ list, recognizing top-performing companies from over 1,600 TSXV issuers based on market capitalization growth, share price appreciation, and trading volume. The mobile clinical network and medical platform also achieved significant recognition in 2024, ranking 9th in Canada and 56th in North America on Deloitte's Technology Fast 500 list.

The company's VSDHOne telemedicine and e-commerce platform is now fully operational across all 50 U.S. states. CEO Shane Madden highlighted their commitment to innovation in mobile healthcare and telemedicine, focusing on enabling licensed healthcare professionals to deliver care at home, in clinics, and through direct-to-consumer models.

Looking ahead to 2025, Hydreight plans to focus on scaling VSDHOne and the Accelerator Program, optimizing product offerings for higher margins, and exploring 503A and 503B licensing opportunities for vertical integration.

Hydreight Technologies (HYDTF) has expanded its VSDHOne platform by launching Nicotinamide Adenine Dinucleotide (NAD+) therapy in three new delivery formats: patch, injection, and nasal spray. This expansion targets the growing anti-aging market, valued at $73 billion in 2024 and projected to reach $140.94 billion by 2034.

The company now offers NAD+ through three delivery methods: intramuscular/subcutaneous injection for rapid absorption, daily intranasal spray for convenience, and IonToPatch featuring 4-hour wear time and 80 mA/min delivery with 1mL fill volume. NAD+ therapy aims to provide benefits including improved cognitive function, enhanced energy levels, weight management support, and potential neuroprotective effects.

This development strengthens Hydreight's position in providing accessible wellness solutions through its nationwide telehealth network across 50 U.S. states.

Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has announced a strategic partnership with The DRIPBaR to launch 'DRIPBaR Direct,' a nationwide direct-to-consumer healthcare initiative. The service will be powered by Hydreight's VSDHOne platform, enabling The DRIPBaR to expand its IV therapy and wellness services across the United States.

The partnership follows a successful pilot phase that demonstrated increased client engagement and operational efficiency. Through the VSDHOne platform, clients can submit health information online, connect with licensed medical professionals remotely, and receive physician-prescribed wellness treatments for self-administration at home.

This collaboration combines Hydreight's mobile clinical network, which operates across 50 states, with The DRIPBaR's expertise in preventive healthcare and IV therapy solutions. The initiative aims to enhance accessibility to personalized health and wellness services, allowing The DRIPBaR to scale its digital health offerings to all franchise locations.

Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) and Victory Square have announced a $10 million D2C Digital Health Accelerator program through their VSDHOne platform. The initiative aims to support emerging healthcare brands across the United States by providing funding, resources, and platform access.

The program targets companies offering various treatments including skincare, hair loss, sexual health, weight management, and longevity solutions. To qualify, companies must have minimum revenue of $750,000 USD in the last 12 months, US-based operations, and commit to migrating to the VSDHOne platform.

Selected companies will receive funding through a combination of services, cash, and stock, along with access to VSDHOne's telehealth infrastructure, e-commerce solutions, nationwide compliance, marketing support, and a network of healthcare professionals. The initiative addresses inefficiencies in the US healthcare system, projected to reach $7.2 trillion by 2031.

Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) reported significant achievements in 2024, including the successful launch of VSDHOne, a telemedicine platform now operating in all 50 states with over 200 licenses sold. The company achieved record financial performance with $6.12 million in Q3 2024 revenue, representing a 54% year-over-year increase, and reached positive adjusted EBITDA.

The company reported $16.58 million in topline revenue for the first 9 months of 2024, a 37% increase compared to 2023. Hydreight was ranked 56th on Deloitte's Technology Fast 500™ in North America and 9th on Deloitte Canada's Technology Fast 50™.

For 2025, Hydreight plans to expand its platform by introducing comprehensive at-home testing services, driving organic growth through strategic acquisitions, and investing in technology partnerships. The company aims to address inefficiencies in the $4.9 trillion U.S. healthcare market through its national network of physicians, nurses, pharmacies, and compliance technology.

Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has launched VSDHOne, a comprehensive Direct-to-Consumer healthcare platform now operational across all 50 U.S. states. The platform enables businesses to create their own healthcare brands with features including telemedicine technology, nationwide doctor networks, pharmacy fulfillment, and medical direction.

VSDHOne currently offers approximately 40 products across categories including skincare, hair loss, sexual health, hormone replacement therapy, and GLP-1 weight management. The platform operates on a SaaS model, with customers purchasing state-specific licenses and paying per-order fees. Since its Q2 2024 soft launch, VSDHOne has onboarded over 200 licenses and projects to reach 1,000 licenses by December 2025, with each license expected to process 5-20 orders daily.

Hydreight Technologies reported strong Q3 2024 financial results with record topline revenue of $6.12M, marking a 54% increase year-over-year. The company achieved positive Adjusted EBITDA of $48K compared to ($265K) in Q3 2023. GAAP revenue reached $4.53M, up 47% from Q3 2023, with gross margins of $1.53M. The company launched VSDHOne, a telemedicine solution, selling over 200 licenses across 50 states in its first 90 days. Hydreight was ranked 56th on Deloitte's Technology Fast 500™ and 9th in Canada's Fast 50 Program for 2024.

Hydreight Technologies has achieved significant recognition in Deloitte's prestigious technology rankings for 2024, securing the 56th position in North America's Technology Fast 500™ and ranking 9th in Canada's Technology Fast 50. The rankings showcase North America's fastest-growing companies across technology, media, telecommunications, life sciences, fintech, and energy tech sectors. Companies on the 2024 Technology Fast 500™ list demonstrated revenue growth ranging from 201% to 186,373% over three years, with average and median growth rates of 2,100% and 460% respectively. To qualify, companies must have proprietary technology, minimum operating revenues of US$50,000 in the base year and US$5 million in the current year.

Hydreight Technologies has secured the 9th position in Deloitte's 2024 Technology Fast 50™ awards program, recognizing Canada's fastest-growing technology companies based on revenue growth from 2020 to 2023. As a mobile clinical network and medical platform, Hydreight's achievement highlights its significant organic revenue growth and market position. The company, which was previously named one of Canada's Companies-to-Watch in the same program last year, qualified by meeting criteria including minimum revenue requirements of $50,000 in 2020 and $5 million in 2023, proprietary technology ownership, and investing at least 5% of gross revenues in R&D activities in Canada.